Revolve Wealth Partners LLC Has $267,000 Stake in Kenvue Inc. (NYSE:KVUE)

Revolve Wealth Partners LLC trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 5.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,553 shares of the company’s stock after selling 727 shares during the period. Revolve Wealth Partners LLC’s holdings in Kenvue were worth $267,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Manchester Capital Management LLC boosted its position in shares of Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after acquiring an additional 530 shares in the last quarter. Mather Group LLC. acquired a new stake in shares of Kenvue during the 1st quarter valued at about $28,000. Riverview Trust Co acquired a new stake in shares of Kenvue during the 3rd quarter valued at about $30,000. MV Capital Management Inc. boosted its position in shares of Kenvue by 71.2% during the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after acquiring an additional 642 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in shares of Kenvue during the 1st quarter valued at about $33,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 1.3 %

Shares of NYSE KVUE opened at $21.72 on Friday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $23.55. The company has a market cap of $41.59 billion, a PE ratio of 27.85, a P/E/G ratio of 2.76 and a beta of 1.40. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average of $22.26 and a two-hundred day moving average of $20.20.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The company’s revenue was down .3% on a year-over-year basis. As a group, equities analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.78%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is 105.13%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KVUE. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a research report on Tuesday, September 24th. Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. boosted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Citigroup reduced their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.20.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.